ArticleFrontiers in pharmacology2022

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer.

Meiyu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.